Trials / Completed
CompletedNCT02979912
Autologous Platelet Lysate in Corneal Epithelial Defects
The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Hanan Jafar · Academic / Other
- Sex
- All
- Age
- 21 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.
Detailed description
Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Platelet Lysate | Eye drops of Platelet Lysate |
Timeline
- Start date
- 2017-02-16
- Primary completion
- 2019-01-15
- Completion
- 2019-01-30
- First posted
- 2016-12-02
- Last updated
- 2021-03-03
Locations
1 site across 1 country: Jordan
Source: ClinicalTrials.gov record NCT02979912. Inclusion in this directory is not an endorsement.